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In Brazil, the patient with severe heart failure listed in transplant row is maintained with inotropic 
drugs, in special the dobutamine. Different from developed 
countries where there are mechanical assistance devices 
to assist in the treatment of these patients along with this 
type of drug.
The use of dobutamine correlates with the presence 
of Eosinophilic Myocarditis (EM), a rare disease in 
which infiltrate eosinophilic occurs. It is mainly related 
to hypersensitivity reaction and hematological diseases. 
For present nonspecific signs, it is rarely diagnosed 
antemortem1. The studies indicate an incidence of 0.5% in 
autopsy series and 23% in explanted hearts after cardiac 
transplantation2,3,4. According to a study that evaluated 
the relationship of drugs with EM, 86% of patients with 
Eosinophilic Myocarditis received dobutamine3. Being the 
drug more involved with this entity, which explains the 
difference in the incidence.
Clinical manifestation is very ranging, from 
asymptomatic cases to conditions as cardiogenic shock and 
sudden death from ventricular arrhythmias. The nonspecific 
signs are cardiac chest pain, dyspnea, fatigue, palpitations 
and syncope. Furthermore, allergic manifestation such as 
fever, rashes and blood eosinophilia may occur5. However, 
symptoms and signs of hypersensitivity are not present in 
all patients6. And there is no consistent association between 
these and the severity of myocardial involvement7.
Moreover, the eosinophilic myocarditis, at the time 
of transplantation, correlates with highs rejection rates. 
Which coincides with the reduction of immunosuppressive 
drugs8.
Thus, the patient may have its clinical condition 
aggravated by this disease. Considering that the average 
waiting for a transplant is 45 days for a patient Intermacs 3, 
with an inotropic dependence9, to understand this entity is 
fundamental because it interfere directly with the patient’s 
life in row.
Few studies in the literature correlate Eosinophilic 
Myocarditis and the use of inotropes. And in our service, 
257
Oliveira VV, et al. Eosinophilic myocarditis and heart transplantation.
the use of dobutamine is more prolonged and the etiologies 
are different. As chagasic disease for which there is no data 
in the literature correlating with ME.
Thus, our study presented at the XXXVI COMU, 
with the title “Assessment of the impact of eosinophilic 
myocarditis in patients submitted to heart transplant in 
use of inotropic drugs”, consists in a database survey of 
patients submitted to heart transplant, where we evaluated 
the prevalence of this entity, clinical and laboratory markers 
and correlations with mortality and rejection. The results 
of this work may guide the detection of the problem and 
allow new approaches, propitiating a better state to the 
patient that is waiting for the transplant. 
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